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Novel Synergistic Therapy for Metastatic Breast Cancer: Magnetic Nanoparticle Hyperthermia of the Neovasculature Enhanced by a Vascular Disruption Agent Introduction
Vascular disruption agents (VDAs) have been shown to selectively destroy established tumor vasculature, which results in the ischemic death of up to 99% of tumor cells [1] . The weakness of this therapy alone is that it often leaves a rim of surviving tumor cells which can then regrow and spread [1] . The overall goal of this study (addressed in Task 2) is to enhance VDA therapy by inducing hyperthermia, targeted to the neovascular endothelium, through the use of superparamagnetic iron oxide nanoparticles (SPIONs) , in order to halt, or significantly slow down tumor growth. Therefore, the first aim of this study (Task 1) is to maximize the delivery of SPIONs to the tumor rim, through a combination of targeting and increase vascular permeability induced by the VDA.
Targeted therapy takes advantage of biomarkers that are characteristic of the tumor environment in order to selectively treat tumor cells [2] . Angiogenesis, the process by which new blood vessels are formed, plays a crucial role in development, wound repair, and inflammation [2] . This process is exploited in cancer, and is essential for tumor growth beyond the size of about 1-2 mm in diameter [8] . The integrin receptor αvβ3, which is over-expressed on the activated endothelium of tumor neovasculature, is a glycoprotein membrane receptor which recognizes ECM proteins expressing an arginine-glycine-aspartic acid (RGD) peptide sequence [3, 10] . The integrin receptor αvβ3 is a strong potential anti-angiogenic target because it is up-regulated in both cancer cells and tumor associated blood vessels [9] . Peptide ligands containing the RGD triad display both a strong affinity, as well as selectivity to the αvβ3 integrin [11, 19] . However, in our work, SPIONs, when bound directly to the RGD containing peptide c(RGDfK), demonstrated poor specific binding when compared to controls. Though the conjugation was shown to be successful, these results could be due to mis-orientation of c(RGDfK) on the particle surface, or steric hinderance from SPIONs at the active site for αVβ3 integrin. To target αvβ3, SPIONs were first conjugated to a small molecule ligand, cyclic RGD, c(RGDfK).
Observed functional inactivity of the RGD-conjugated particles led to the replacement of the c(RGDfK) ligand with an antibody against vascular endothelial growth factor receptor 2 (αVEGFR-2). An antibody against VEGFR-2 was selected to replace the c(RGDfK) conjugate because of the role of VEGFR-2 overactivation in angiogenesis [2] . VEGFR-2 is a receptor tyrosine kinase expressed primarily at the surface of endothelial cells, which is auto-phosphorylated through stimulation by circulating VEGF-A to induce endothelial proliferation [4] . High levels of tumor VEGF-A production, shown to up-regulate VEGFR-2 gene expression, correlates with the over-expression of VEGFR-2 at the tumor vasculature [4] . αVEGFR-2 targeted contrast agents have been shown to correlate with the relative expression of VEGFR-2 and the vascular phenotype of tumors in mouse models, demonstrating the effectiveness of this modality [12] .
The cross-reactivity of αVEGFR-2 in both mice and humans was also an important intention in our selection of the antibody clone, because the MDA-MB-231 xenograft tumor cells are human derived, whereas the host for the tumor is a NOD SCID mouse. Therefore the tumor will consist of human breast cancer cells, and the vasculature will consist of mouse endothelial cells. Thus a clone that reacts with both mouse and human VEGFR-2 was chosen. Further, the activity of αVEGFR-2 targeted SPIONs was tested in vitro on human umbilical vein endothelial cells (HUVEC), so the ability to use an antibody with a similar affinity for human and mouse VEGFR-2 simplified the determination of whether the SPION conjugation was successful. The functionalization of αVEGFR-2-conjugated SPIONs was successfully demonstrated by their specific association with the cell surface of human umbilical vein endothelial cells (HUVEC) when compared to a nonspecific Immunoglobulin G (IgG)-conjugated SPION control.
In addition to targeting, we hypothesize that VDAs may co-facilitate SPION delivery to the tumor rim. The initial changes at the active tumor endothelium which are induced by VDAs include the reorganization of the cytoskeletal network and the alteration of the junctions between endothelial cells [13] . This response is generally rapid (within 1 h), and results in the enhanced permeability of the endothelium [13] . Downstream effects triggered by VDAs further lead to the induction of tumor hemorrhagic necrosis [14] , and the ischemic death of up to 99% of tumor cells [1] . In order to demonstrate the enhanced endothelial permeability effects on SPION delivery to tumors, subcutaneous xenograft breast tumor-bearing mice were first treated with DMXAA (5,6-dimethylxanthenone-4-acetic acid), a low-molecular-weight VDA. The delay between DMXAA administration and the injection of the αVEGFR-2 SPIONs that maximizes the SPION concentration in the viable tumor rim was determined by the time variable delivery (15 min, 30 min, or 60 min) of αVEGFR-2 conjugated SPIONs following VDA administration.
Our current results suggest that VDAs appear to enhance the delivery of αVEGFR-2-conjugated SPIONs to the tumor rim, by promoting increased permeability of neovascular endothelial cells [4] . To demonstrate VDA enhanced delivery, NOD-SCID mice were induced with two subcutaneous xenograft MDA-MB-231 breast tumors. The first group of mice was treated with either αVEGFR-2-conjugated SPIONs, IgGconjugated SPIONs, or unconjugated SPIONs (PEG only) both without VDA treatment. A second group is currently being assessed under time variable delivery of αVEGFR-2-conjugated SPIONs, IgG-conjugated SPIONs, or unconjugated SPIONs (PEG only) following VDA treatment. The effects of these treatments are observed qualitatively through Prussian blue histology in order to determine the conditions for maximum SPION delivery to the tumor rim. To quantify the nanoparticle delivery to tumors in vivo, we attempted to use chemical analysis (by inductively coupled plasma mass spectrometry, ICP-MS) to detect the iron delivered to the tumors in the form of SPIONs. Unfortunately, we found that while ICP-MS is sensitive enough to quantify the iron at levels appropriate to monitor nanoparticle delivery to tumors, the endogenous background levels of iron in breast tumor tissue are significant and variable; the variation observed in normal tissue was unfortunately greater than the quantity of iron to be delivered as nanoparticles.
Further changes in neovascular permeability in response to VDAs, which include the induction of endothelial apoptosis [16] , blood vessel rupture, and a boost of N 2 O [17] are all reported to occur after about 12-24 h. We hypothesized that these late alterations in tumor physiology after VDA treatment may also be favorable to increasing SPION delivery. In the process of evaluating this hypothesis in vivo, we discovered that the tumor-bearing NOD/SCID mice were not surviving DMXAA pre-treatment for more than 6 hours. This led the development of a new bicarbonate formulation of the drug that was well-tolerated over many days. With the new DMXAA formulation, we then performed a number of experiments, including verification (using Hoechst staining) of the drug's ability to alter perfusion/permeability in tumors and tests of whether longer VDA pretreatments (20 hours) increase SPION delivery to the tumor rim.
Having determined methods for increasing SPION delivery to tumors in this study, targeted hyperthermia will be induced in vivo in future studies by exposing the SPIONs to an alternating magnetic field (AMF). When exposed to an AMF, SPIONs generate heat as a result of hysteresis and relaxational losses, which results in the heating of tissue in which SPIONs accumulate [5] . We will also investigate whether the heating effect can be utilized to trigger release of additional chemotherapeutic from drug-loaded nanoparticles.
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Materials and Methods
SPION Surface Functionalization
The conjugation of c(RGDfK) peptide to 15 nm carboxyl functionalized SPIONs was performed using a covalent link with the amine group of the peptide and the carboxyl group of the SPIONs using the Ocean NanoTech Carboxyl Magnetic Iron Oxide Nanocrystals Conjugation Kit. First, 0.2 mL of SPIONs (5 mg Fe/mL) were activated by incubating with a molar ratio 2000:1 of sulfo-N-hydroxysuccinimide and 1-ethyl-3, 3-dimethylaminopropyl carbodiimide hydrochloride (EDAC) for 20 min in a borate buffered solution, pH 5.5, after which the pH was adjusted to 8.0. The protein (0.2 mg) was added immediately, mixed well, and incubated for 2 h at room temperature. The resulting nanocrystal conjugates were purified by centrifugation at 18350 RCF (12800 RPM) twice for 1 h each, and stored in 1 mL borate buffered solution, pH 7.4. This method was repeated using 0.2 mg c(RADfK) peptide as a negative control. In order to separate the RGD binding sequence further from the particle surface as a way to overcome steric hinderance, this method was repeated for 0.2 mg c(RGDfK)(PEG-PEG)) peptide. This RGD analog contains two PEG derivatives (8-amino-3,6-dioxaoctanoic acids) that act as spacers between ligand and lipid head groups, to allow for more efficient binding [20] . For these experiments c(RADfK(PEG-PEG)) was conjugated by the same methods as a negative control.
For antibody conjugated SPIONs, these methods were repeated using 0.02 mg polyclonal αVEGFR-2. As a negative control, 0.02 mg of polyclonal normal mouse immunoglobulin G (IgG) was conjugated to SPIONs, also by the same methods.
In order to improve SPION circulation time for more effective tumor delivery in vivo, these methods were repeated for 0.02 mg polyclonal αVEGFR-2, as well as 0.02 mg IgG using particles which were functionalized with a PEG-Carboxyl coating. The polymeric PEG coating acts to further stabilize the particles, and has been shown to increase the blood half-life of particles in vivo by up to 5 fold [15] . 
Conjugated SPION Quantification
Stock 15 nm carboxyl functionalized SPIONs were diluted from a concentration of 5 mg Fe/mL to three individual cuvettes at 0.04 mg/mL, 0.02 mg/mL, and 0.01 mg/mL in di-H2O. A full spectrum absorbance of each solution was generated using a Beckman Coulter DU 800 UV/Vis Spectrophotometer. To generate a standard curve, the absorbances at 350 nm for these particle solutions were plotted as a function of SPION concentration. Conjugated SPIONs (with unknown concentrations) were each diluted 1:500 in di-H2O, and their concentrations were determined by plotting individual absorbances at 350 nm on the standard curve.
Because the carboxylic acid functional groups of SPIONs are strongly anionic when free, compared to when conjugated to protein, they freely form carboxylate salts with metal cations. If the surface charge is providing colloidal stabilization (i.e., the repulsion of like surface charges prevents the particles from aggregating), this shielding of the surface charge by ions can lead to aggregation and the precipitation of SPIONs in ionic solutions. To determine successful conjugation, 0.1 mg of SPIONs were mixed with 0.4 mL of serum free Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12 (DMEM/F-12), which contains divalent cations for the purpose of cell culture. Visual inspection of the solution to look for particle stability was then compared 1 h after mixing in order to determine successful conjugation. Differences in this form of colloidal stability between un-conjugated and conjugated SPIONs imply that the surface modification was successful.
Cell Surface Receptors Antibody
Cell Culture Conditions HUVEC line was cultured at 37° C under a humidified atmosphere of 5% CO2 and 95% air in MCDB-131 complete medium with fetal bovine serum and antibiotics (VEC Technologies) on gelatin coated surface. SK-0V-3 ovarian adenocarcinoma cell line was cultured at 37° C under a humidified atmosphere of 5% CO2 and 95% air in McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin:streptomycin. MDA-MB-231 and MDA-MB-435 mammary gland adenocarcinoma cell lines were cultured at 37° C under a humidified atmosphere of 5% CO2 and 95% air in DMEM/F-12 supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin:streptomycin.
Conjugated SPION Cell Targeting
Cultured cells were divided into 4x6 well plates over poly-L-lysine coated cover slips at a concentration of 1x10 5 cells per well, and cultured overnight. The optimum SPION concentration for short-term cell targeting in culture was determined by preparing 2.5 mM incremental solutions within the range of 0 mM to 15 mM of c(RGDfK) conjugated SPIONs in serum free DMEM/F-12 media. Time dependence for the receptor mediated endocytosis of particles was then determined by incubating cultured cells with each solution in 15 min increments up to an hour at 37° C. All SPION incubations which followed were carried out with a 10mM solution of conjugated SPIONs in serum free culture media for 30 min. Adherent cells were washed with PBS, and fixed using 4% paraformaldehyde (PFA) in PBS buffer solution for 15 min. Fixed cells were then washed twice with PBS. These conditions were repeated for αVβ3 targeting using c(RADfK) conjugated SPIONs as a control. Conditions were also repeated using c(RGDfK)(PEG-PEG)) conjugated SPIONs and c(RADfK)(PEG-PEG)) conjugated SPIONs as a negative control. Finally, for VEGFR-2 targeting, these conditions were repeated using αVEGFR-2 conjugated SPIONs and IgG conjugated SPIONs as a control.
SPION Staining
Prussian blue is produced by mineral acid hydrolysis to release ferric ions, which then form a dark blue precipitate in the presence of ferrocyanide ions by the following reactions [21] :
This staining method was performed on fixed cells by incubating with equal parts 10% potassium ferrocyanide and 20% hydrochloric acid for 20 min. Cells were washed 3 times with di-H2O and counterstained with nuclear fast red for 5 min. Stained cells were washed again 2 times with di-H2O and mounted using VECTASHIELD mounting medium with DAPI. The presence of antibody conjugated SPIONs was also detected using a secondary, fluorescent antibody. This was performed by first incubating fixed cells with blocking serum (3% normal goat serum) for 30 min with continuous mixing. Cells were then washed twice with PBS and incubated with a 1:250 solution of secondary antibody (rabbit α mouse 488) in PBS for 30 min with continuous mixing. Labeled cells were washed with PBS and mounted using VECTASHIELD mounting medium with DAPI. For each secondary antibody labeled experiment, a negative control was used which did not receive particle or antibody treatment.
Conjugated SPION Murine Tumor Delivery
Female NOD-SCID mice were bred at the University of New Mexico Animal Resource Facility. All mouse procedures were performed according to a protocol approved by the University of New Mexico Health Sciences IACUC. Prior to injection, MDA-MB 231 cells were collected and suspended with 50% MatriGel in DMEM/F-12 media and kept on ice. Two million cells were injected into each of the inguinal mammary fat pads of the NOD-SCID mice at 6-8 weeks of age. Tumor development was monitored weekly until the outer diameter reached about 10 mm in size.
On
in 4% paraformaldehyde in PBS buffer solution overnight, and embedded in paraffin for sections. Tissue sections were deparaffinized and hydrated to water, stained using Prussian blue histology, dehydrated, cleared in xylene, and mounted in Permount.
For VDA treated mice, DMXAA was dissolved in 10% DMSO/PBS and given to mice by intraperitoneal injection at a dose of 20 mg/kg, which is typical for other mouse studies [22] . However, this formulation was eventually shown to produce an adverse reaction (leading to pre-mature death) cause by the DMSO in tumorbearing NOD/SCID mice. A new formulation was developed to eliminate the DMSO. DMXAA was dissolved in 5% sodium bicarbonate to produce a 10 mg/ml solution, then diluted 1:2 in 1x PBS to produce a 5 mg/ml solution, resulting in an approximately 100 microliter injection volume. The bicarbonate formulation produced no adverse reactions, but was shown to alter tumor vascular physiology in the desired manner (see results below). 
Results
SPION Surface Conjugation
A cross-linking reaction with carboxyl functionalized SPIONs using EDAC as an activating agent to couple the carboxyl groups on particles to amino-terminal groups on the antibody or peptides yielded particles with functional biocompatibility. Carboxyl-SPIONs conjugated with protein exhibited greater colloidal stability at biological pH, salinity, and temperature conditions compared to un-conjugated SPIONs, which formed a precipitate in culture medium (Figure 2 ). The addition of protein apparently provided steric stabilization, i.e. the protein provided a spacer that prevented particles from getting close enough together to aggregate due to attractive VanderWaals interactions. Because PEG-Carboxyl particles show native stability in biological pH, salinity, and temperature conditions prior to conjugation, no difference in solubility was observed following conjugation for PEG-Carboxyl particles. The PEG molecules provided steric stabilization, such that further addition of protein does not increase the stability. SPIONs conjugated with αVEGFR-2 antibody were effectively labeled with a secondary fluorescent antibody (rabbit α mouse 488). Furthermore, αVEGFR-2 conjugated showed a high level of binding to HUVECs (which express high levels of VEGFR-2) compared to an IgG conjugated SPION control, which showed a low level of binding ( Figure 6 ). The absorbances of known concentrations of a standard (stock carboxyl-SPIONs) were measured at 350 nm, which was used to determine the concentrations of conjugated SPION solutions (Figure 3 ). 
Particle Type Estimated Concentration Measured Concentration
Percent Yield C-VEGFR2 1 mg/ml 0.595 mg/ml 59.5% PC-VEGFR2 1 mg/ml 0.896 mg/ml 89.6% C-IgG 1 mg/ml 0.843 mg/ml 84.3% PC-IgG 1 mg/ml 0.767 mg/ml 76.7% 
β3 Immunohistochemistry (IHC)
IHC was carried out to show the relative expression of αVβ3 integrin in cells. HUVEC, MDA-MB-231, and MDA-MB-435 cell lines were also included along with SK-OV-3 cells as a positive control, as well as to correlate the relative presence of αVβ3 with c(RGDfK) conjugated SPION activity. For this experiment, adherent cells were first lifted using EDTA, and suspended during incubations in order to view αVβ3 presence on all sides, including adherent portions of the cell surface. A polyclonal β3 antibody containing an RGD sequence was used to label cells. This staining was successful in all cell types, with the greatest overall presence of αVβ3 integrin shown in SK-OV-3 ( Figure 4A ) and MDA-MB-231 ( Figure 4B ) cell lines. A. B.
(A) SK-OV-3 cells 32x. SPIONs covalently conjugated to c(RGDfK), which selectively binds to αVβ3.
(B) SK-OV-3 Cells 32x. SPIONs covalently conjugated to c(RADfK), which does not bind αVβ3 as a negative control.
Particles are visible in blue, and Nuclei in red following prussian blue histology. The lack of difference between the c(RGDfK) conjugated, and c(RADfK) conjugated control SPIONs suggests that only non-specific binding occurs.
c(RGDfK)(PEG-PEG))-SPION Incubation
Accounting for possible steric hindrance from particles being too closely associated with RGD peptide, SPIONs were conjugated with c(RGDfK)(PEG-PEG)) peptide. This analog contains two mini-PEG derivatives (8-amino-3,6-dioxaoctanoic acids) that act as spacers between the ligand and the particle surface to allow for more efficient binding [20] . For this experiment, HUVEC, MDA-MB-231, and MDA-MB-435 cell lines were included along with SK-OV-3 cells to correlate the relative presence of αVβ3 with functionalized SPION activity. Particle internalization was again generally minimal, with no observable difference between cell types or conjugates. This again suggests that only non-specific binding occurs for c(RGDfK)(PEG-PEG)) conjugated SPIONs.
αVEGFR-2 Conjugated SPIONs
HUVECs, having the highest confirmed expression of VEGFR-2 from IHC, were used for particle incubations with αVEGFR-2 conjugated SPIONs, and with IgG conjugated SPIONs as a negative control. After incubations, cells were fixed, incubated with a blocking agent, and lastly incubated with secondary antibody to reveal labeled particles attached at the cells surface. αVEGFR-2 conjugated SPIONs ( Figure 5A ) demonstrated effective functionalization, binding around the cell surface at high concentrations, while IgG conjugated SPIONs ( Figure 5B ) were only found minimally associated with cells. 
Conjugated SPION Murine Tumor Delivery
When injected with carboxyl-SPIONs which were conjugated to αVEGFR-2, particles were apparently quickly cleared, with no tumor delivery observed. Carboxyl-SPIONs were then replaced by particles with a PEGCarboxyl surface functionalization. The polymeric PEG coating acts to improve the stability of particles, and has been shown to increase the blood half-life of particles in vivo by up to 5 fold [15] . These particles show sustained stability in biological conditions, but also demonstrate reduced binding to HUVECs ( Figure 7A ) compared to VEGFR-2 conjugated particles without PEG ( Figure 6A) . However, the addition of PEG has the benefit of reducing non-specific binding of IgG-conjugated particles (the negative control condition) to HUVECs (comparing Figure 6B to Figure 7B ). When injected alone, a small degree of αVEGFR-2-SPION localization at the tumor rim was observed ( Figure 8B ). Delivery was qualitatively increased when the particles were injected at 15 min following VDA treatment ( Figure 8A ). Tumor delivery was reduced however when αVEGFR-2-SPIONs were injected 30 min following VDA treatment. (A) Mouse tumor section at 20x. αVEGFR-2 conjugated SPIONs 15 min following VDA treatment show enhanced particle delivery to the tumor rim.
(B) Mouse tumor section at 20x. αVEGFR-2 conjugated SPIONs without VDA treatment show some particle delivery to the tumor rim when given alone.
Further changes in neovascular permeability in response to VDAs, which include the induction of endothelial apoptosis [16] , blood vessel rupture, and a boost of N 2 O [17] are all reported to occur after about 12-24 h. We hypothesized that these late alterations in tumor physiology after VDA treatment may also be favorable to increasing SPION delivery. In the process of evaluating this hypothesis in vivo, we discovered that the tumor-bearing NOD/SCID mice were not surviving DMXAA pre-treatment for more than 6 hours. This was perplexing, given that non-tumor-bearing mice, used in our initial testing of the DMXAA dosing, showed no adverse effects. Given that our ultimate goal is to evaluate combination VDA/SPION treatment of tumors over a period of weeks, the poor long term survival after DMXAA administration was a critical issue to address. Further evaluation of the problem revealed that tumor-bearing mice (but not normal mice) were having an adverse reaction to the DMSO used to dissolve the poorly-soluble DMXAA into a volume that could be safely injected. Further research revealed that a 5% sodium bicarbonate buffer could be used to dissolve the drug in a reasonable volume, and the new bicarbonate formulation was well-tolerated by normal and tumor-bearing mice over many days. With the new DMXAA formulation, we then performed a number of further experiments, including 1) verification (using Hoechst staining) of the drug's ability to alter perfusion/permeability in tumors (Figure 9 above) and 2) tests of whether longer VDA pre-treatments (20 hours) increase SPION delivery to the tumor rim (data not shown). Using Hoechst staining (delivered intravenously immediately prior to sacrificing the mice), we verified that the bicarbonate formulation of DMXAA produces an increase in deposition of the dye in tumor tissue following DMXAA administration. The increase in the volume of the tumor that stains blue after DMXAA treatment suggests that the VDA is having the desired effect of increasing perfusion/vascular permeability, which allows more dye to reach tumor tissue. Experiments performed using NOD/SCID mice with xenograft tumors to assess whether a longer period of VDA pre-treatment (20 hours) would be effective at increasing SPION delivery to tumors. These experiments revealed no difference between No VDA and 20 h VDA pretreatment (data not shown).
Based on Dr. Hathaway's recent experience with the PyMT tumor model (not originally proposed for use in this study), we felt that it would be worthwhile to test the DMXAA 15 minute pre-treatment combined with VEGFR2-PEG-SPIONs in the PyMT model, because we hypothesized that the PyMT tumors would be bettervascularized. The PyMT model we used is a transgenic mouse (on a FVB background) that spontaneously and reliably develops mammary tumors at 10 weeks and metastases (primarily lung) at approximately 14 weeks. The tumors are therefore not xenografts but are instead malignant mouse mammary cells. Thus all components of the tumor environment (blood vessels, stroma, tumor) are formed from mouse cells. Unlike xenograft models, which require an immunocompromised mouse to avoid rejection of the tumor, the PyMT mouse model is an immune-competent mouse with a fully functioning immune system. Thus the PyMT tumor microenvironment also includes immune cell populations (such as tumor-associated macrophages) similar to those found in human breast tumors. 
Quantitation of SPIONs delivered In Vivo
As shown in Figure 12 below (left graph), we determined that inductively coupled plasma mass spectrometry (ICP-MS) of iron is sensitive enough to quantify the microgram quantities of iron that we expect to deliver to tumors in the form of iron-oxide nanoparticles. Unfortunately, further quantitative assessments of tumor tissue (which showed varying levels of SPION delivery by Prussian blue microscopy) revealed no clear trend in the iron content of the tumor tissue by ICP-MS.(data not shown) Further investigation revealed that the background endogenous iron levels in breast tumor tissue are of order 10-20 micrograms Fe per gram tissue ( Figure 12 , right graph), and the variation (several micrograms/g) is greater than the expected total iron content of SPIONs delivered to tumors. Thus the ICP-MS method is sensitive enough, but not specific enough, to quantify iron from SPIONs in tumor tissue. The issue of quantifying SPION delivery will need to be addressed in a future study. 
SPION heating under Alternating Magnetic Field Conditions
In preparation for in vivo testing of hyperthermia therapy (Task 2), SPIONs in aqueous solution were exposed to a biocompatible alternating magnetic field (AMF), i.e. using a field strength and frequency safe for normal tissue. The sample chamber was maintained at a background temperature of 37 deg. C, suitable for future in vivo testing. A sample containing only water (no nanoparticles) showed a temperature rise <1 deg C after 20 minutes, which demonstrates that the AMF conditions are safe for normal tissues. Ocean SHP-20 SPIONs yielded the greatest heating capacity and will be used in future in vivo studies of hyperthermia therapy. 
Discussion
When compared to unconjugated carboxyl functionalized SPIONs, c(RGDfK)-conjugated carboxyl SPIONs show greater colloidal stability at physiological pH and salinity, indicating a successful conjugation. In vitro, these SPION conjugates were, however, ineffective at targeting cell types shown by IHC to highly express the receptor for the RGD ligand (αvβ3 integrin). This could be due to the misorientation of c(RGDfK) following the conjugation, steric hindrance from the overcrowding of peptide on the particle surface, or possibly due to the steric hindrance of ligand/receptor interaction from particles themselves. Attempts to reduce steric hindrance using a c(RGDfK) peptide with a PEG linker (to extend the distance between the RGD and the nanoparticle surface) were also unsuccessful. When conjugated to αVEGFR-2 antibody, SPIONs demonstrated effective in vitro targeting of VEGFR-2 expressing human epithelial cells. The antibody clone chosen has also been shown to react with mouse VEGFR-2. While this model was effective for cell targeting under culture conditions, tumor models provide additional obstacles to overcome for SPION delivery. Initial injections of SPIONs in tumor bearing mice resulted in the apparently rapid clearance of particles (particles observed in liver, spleen, and to a small extent, lung), with no tumor delivery. In order to improve SPION circulation time for more effective tumor delivery, carboxyl-SPIONs were replaced by particles which were functionalized with both a PEG and carboxyl coating. The added stability of including PEG on the surface of αVEGFR-2-SPIONs coincided with a reduction in binding to HUVECs in vitro, but also a desirable reduction in non-specific binding of IgG-SPIONs to HUVECs. The reduced binding of αVEGFR-2-SPIONs to HUVECs is presumed to be due to a reduction of the conjugation efficiency of αVEGFR-2 to SPIONs, because the presence of PEG reduces the number of carboxyl sites on the particle surface. These particles did, however, demonstrate a modest level of delivery to the tumor rim when injected alone into mice (i.e. without the addition of VDA). Thus the addition of PEG appears to be beneficial for in vivo delivery of these particles.
The initial VDA response, which results in the alteration of the junctions between endothelial cells, [13] appears to increase the delivery of αVEGFR-2-conjugated SPIONs to the tumor rim when the particles were injected 15 min after DMXAA. A lower level of delivery was observed from IgG-conjugated SPIONs under the same VDA conditions. Overall, the combination of VEGFR-2 targeting and 15 min. pre-administration of VDA appears to act synergistically to increase SPION delivery to the tumor rim. These results, which have been assessed qualitatively using Prussian blue histology could not be confirmed quantitatively (by iron mass spectrometry), due to the high endogenous iron concentration in breast tumor tissue.
Further changes in neovascular permeability in response to VDAs, which include the induction of endothelial apoptosis [16] , blood vessel rupture, and a boost of N 2 O [17] are all reported to occur after about 12-24 h. These events could similarly enhance the delivery of SPIONs; however, our study comparing a 20 h pretreatment by DMXAA compared to no DMXAA showed no enhancement of SPION delivery using the 20 h DMXAA treatment. A limited study using an immunocompetent mouse mammary tumor model showed promising results. Transgenic PyMT-FVB mice spontaneously develop tumors in their mammary glands by 10 weeks of age. The advantages of this immunocompetent mouse tumor model include better vascularization of the growing tumor and a tumor microenvironment (including an immunological component, e.g. tumor-associated monocytes and macrophages) that better recapitulates human breast tumors. As we observed previously in a xenograft model (MDA-MB-231 tumors in NOD/SCID mice), there was a noticeable enhancement of SPION delivery to tumor tissue in PyMT mice using a 15 min DMXAA pre-treatment, compared to no DMXAA. Perhaps more importantly, we observed an overall increase in SPION delivery to tumors using the PyMT model. In other words, PyMT tumor-bearing mice, both with and without DMXAA pre-treatment, showed greater and more uniform SPION delivery to tumor tissue, relative to NOD/SCID mice with xenograft tumors under the same experimental conditions. Further, the participation of immune cells in delivering SPIONs to tumor tissue was observed to be more significant in the immunocompetent PyMT model.
The heating which can be achieved by exposing SPIONs to an AMF is shown to be linearly proportional to particle concentration [6] , indicating that effectiveness is directly proportional to delivery. Thus our demonstration that combining the targeted αVEGFR-2 conjugated SPIONs with VDA mediated vascular permeability increases particle delivery is an important first step in developing this therapy. We have further succeeded in identifying a more suitable mouse model (transgenic PyMT-FVB) for testing this therapy going forward. The fact that female PyMT mice develop both primary mammary tumors and lung metastases is an added advantage. Additionally, we have determined a superior formulation for administering the vascular disrupting agent DMXAA required for future longitudinal studies of this therapeutic method.
Problems Encountered Task 1.
